Effectiveness verification of Mirtazapine Patients with Acute Anxiety
- Conditions
- Mental and behavioural disorders
- Registration Number
- KCT0008183
- Lead Sponsor
- Chung-Ang Univerisity Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 52
? The age of 18 to 65
? A person diagnosed as a major depressive disorder without psychotic features. by Structured Clinical Interview for DSM-5 (SCID-5)
? BAI scale score is 16 or higher (with moderate or higher anxiety symptoms)
? Those who have no history of using Mirtazapine in the last two months based on the initial evaluation point
? Those who have been administering antidepressants (SSRI, SNRI and NDRI) at stable doses for more than 1 month
? A person who has been diagnosed other psychiatric diagnosis by SCID-5-CV in the past
? Those who currently have severe medical conditions (cancer, heart failure, kidney failure, liver disease, lung disease, thyroid disease and acute inflammatory conditions)
? A person who has a history of past or present dependence on substances or misuse
? A person with a history of epilepsy, head trauma, and organic mental illness
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method mean change of Beck anxiety inventory (BAI) scores from baseline
- Secondary Outcome Measures
Name Time Method mean change of Beck depressive inventory (BDI-II) scores from baseline;mean change of Korean Symptom Check List 95 (KSCL95) scores from baseline;mean change of CGI-S scores from baseline;CGI-I scores after 8 weeks of intervention;hemodynamic changes in prefrontal cortex measured with functional Near-Infrared Spectroscopy(fNIRS)